Economic Evaluation of Bruton's Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa. [PDF]
Appl Health Econ Health PolicyWoudberg R, Sinanovic E.
europepmc +1 more source
Process for the Preparation of Crystalline Acalabrutinib Maleate Monohydrate [PDF]
Process for the Preparation of Crystalline Acalabrutinib Maleate Monohydrate Acalabrutinib or 4-{8-Amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1- yl}-N-(pyridin-2-yl)benzamide is the active pharmaceutical ingredient (API) in the ...
Anonymous,
core +1 more source
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia. [PDF]
Future OncolShadman M +7 more
europepmc +1 more source
Acalabrutinib treatment in relapsed/refractory primary cutaneous diffuse large B cell lymphoma, leg type. Case report. [PDF]
Front OncolMartinez-Gamboa DA +6 more
europepmc +1 more source
Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. [PDF]
Blood AdvDarnell EP +11 more
europepmc +1 more source
Brute force: the effects of ibrutinib on brexu-cel. [PDF]
Blood AdvPeterson CE, Betts BC.
europepmc +1 more source
Acute Severe Hepatitis B Virus Infection in Previously Vaccinated Patient during Acalabrutinib Treatment. [PDF]
Emerg Infect DisRojek L +4 more
europepmc +1 more source
Latest advances in frontline CLL treatment from the 2025 ASH congress. [PDF]
Ann HematolVisentin A.
europepmc +1 more source
Cutaneous Adverse Effects in Patients Treated with BTK Inhibitors. [PDF]
Cancers (Basel)Robak E, Robak T.
europepmc +1 more source
Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL [PDF]
, 2018 Bartlett, Nancy L.
core +1 more source